Cleveland Story

<div class='circular--portrait' style='background:#008000;color: #FFE4E1;font-size:4em;'>CB</div>
CBLI -- USA Stock  

USD 5.03  0.28  5.27%

The stock goes through an active upward rally. As many baby boomers are still indifferent towards healthcare space, it makes sense to break down Cleveland as a potential position. We will evaluate why we are still optimistic in anticipation of a recovery.
Published over two weeks ago
View all stories for Cleveland Biolabs | View All Stories
Our current take on Cleveland (NASDAQ:CBLI) analyst consensus
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cleveland Biolabs has an asset utilization ratio of 1.26 percent. This implies that the company is making $0.0126 for each dollar of assets. An increasing asset utilization means that Cleveland Biolabs is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of Cleveland Biolabs? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated.
Please read more on our stock advisor page.

How important is Cleveland Biolabs's Liquidity

Cleveland Biolabs financial leverage refers to using borrowed capital as a funding source to finance Cleveland Biolabs ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cleveland Biolabs financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Cleveland Biolabs's total debt and its cash.

How Cleveland utilizes its cash?

To perform a cash flow analysis of Cleveland Biolabs, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Cleveland Biolabs is receiving and how much cash it distributes out in a given period. The Cleveland Biolabs cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Cleveland Biolabs Net Cash Flow from Operations is most likely to increase significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (2.37 Million)

Cleveland Biolabs exotic insider transaction detected

Legal trades by Cleveland Biolabs insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Cleveland insider trading alert for general transaction of common stock par value $0.005 per share by James Antal, the corporate stakeholder, on 19th of March 2021. This event was filed by Cleveland Biolabs Inc with SEC on 2013-03-18. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Cleveland a risky opportunity?

Let's check the volatility. Cleveland is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Cleveland (NASDAQ:CBLI) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. locking in a share of a Cleveland Biolabs stock makes you a part-owner of that company.

Another 3 percent rise for Cleveland Biolabs

Jensen alpha is down to 0.57. It may hint to a possible volatility drop.
As of the 1st of April, Cleveland Biolabs shows the risk adjusted performance of 0.101, and Mean Deviation of 5.09. Cleveland Biolabs technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Cleveland Biolabs, which can be compared to its rivals. Please confirm Cleveland Biolabs jensen alpha, and the relationship between the coefficient of variation and potential upside to decide if Cleveland Biolabs is priced correctly, providing market reflects its regular price of 6.16 per share. Given that Cleveland Biolabs has jensen alpha of 0.5722, we suggest you to validate Cleveland Biolabs's prevailing market performance to make sure the company can sustain itself at a future point.

Our Final Take On Cleveland Biolabs

While some firms within the biotechnology industry are still a little expensive, even after the recent corrections, Cleveland Biolabs may offer a potential longer-term growth to stockholders. To sum up, as of the 1st of April 2021, our overall 30 days buy-sell recommendation on the company is Sell. We believe Cleveland Biolabs is overvalued with high chance of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Cleveland Biolabs. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com